Home News Covid-19

BioNTech gets downgrade from analyst amid vaccine competition

Bloomberg
Bloomberg12/1/2020 03:47 PM GMT+08  • 1 min read
BioNTech gets downgrade from analyst amid vaccine competition
A BioNTech SE analyst advised investors to cash in on their profits from the US$30 billion biotech’s recent advance.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

A BioNTech SE analyst advised investors to cash in on their profits from the US$30 billion ($40.15 billion) biotech’s recent advance, saying the German company now faces heightened competition from peers that are also developing vaccines.

Approval for the company’s Pfizer Inc.-partnered Covid-19 vaccine is already reflected in the stock’s 268% rally this year, so that now there’s limited room for additional gains despite the two companies’ first-mover advantage, BofA analyst Tazeen Ahmad wrote in a note to clients, downgrading BioNTech to neutral from buy.

“The durability of protection remains a key question for the Covid vaccine market,” Ahmad wrote, highlighting competition from the likes of Moderna Inc., AstraZeneca Plc and Johnson & Johnson, among others.

BioNTech American depositary receipts fell as much as 4.4% in late trading Monday after closing at a record. Earlier in the day, Moderna said it planned to request clearance for its coronavirus vaccine in the US and Europe. The move puts it behind Pfizer and BioNTech, which submitted a filing for their shot to US regulators earlier this month.

×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.